Plant-based expression systems are now entering the commercial
arena for biopharmaceutical protein manufacturing and are beginning
to compete directly with conventional fermenter-based platforms
usingmicrobes ormammalian cells. Some plants are starting to emerge
fromthe vast pool of potential species as standard expression hosts. This
declining complexity, together with the standardization of the initial
DSP steps, has already resulted in relevant cost savings during product
recovery operations.Novel technical solutions (e.g.miniaturized laboratory
equipment and continuous DSP operations) and statistical designs
(e.g. DoE software) can be used to exploit and optimize integrated purification
operations such as ATPS, further reducing the production costs
for plant-derived biopharmaceuticals. In this context, plant biotechnology
can take advantage of the lessons learned from fermenter-based
systems and process engineers can begin to implement rational DSP designs
focusing on mechanistic separation models